医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ZRG Partners Life Sciences Hiring Index Q2 Declines Slightly but Still Near Historic High

2014年08月08日 AM04:26
このエントリーをはてなブックマークに追加


 

WEST ORANGE, N.J.

ZRG Partners, Inc. announces the results of its second quarter Global Life Sciences Hiring Index. Q2 displays a slightly negative turn but the overall outlook remains positive with 13% year-over-year gains. The EMEA region, as well as the Outsourcing Services both saw quarterly increases. The Americas was the only region to decline over the quarter.

ZRG Managing Director David Fortier commented, “The continued robust hiring activity is good to see and the growth in both Europe and some previously lagging functional areas is encouraging. The numbers support what our daily interactions with clients candidates indicate – the demand for exceptional talent exceeds the supply.”

About ZRG Partners

ZRG Partners, Inc. is a global authority on talent management issues in the Life Sciences, Pharmaceutical and Medical Device markets. ZRG provides its clients with specialized global market expertise in executive recruitment, consulting and advisory work with a focus on data and analytics to drive great business decisions.

The Global Life Sciences Hiring Index analysis utilizes a proprietary algorithm that looks at confidential hiring within selected benchmark companies in three distinct segments. The companies in the Index generate over $634 billion in revenues and employ over 1,300,000 people globally. ZRG Partners conducts extensive direct market research in developing the data that drives the Index.

For more information about ZRG please go to www.zrgpartners.com

CONTACT

ZRG Partners
Adam
El Din
, +41-22-319-3304
European President and Global Practice
Head of Life Sciences
aeldin@zrgpartners.com
or
David
Fortier
, +1-508-366-5800 x227
Managing Director
dfortier@zrgpartners.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗